Korro stock price surges 17% due to $85 million private placement financing

Investing.com – Korro Bio Inc. (NASDAQ:KRRO) stock rose 17% on Monday after the company announced the completion of an oversubscribed $85 million private placement (PIPE).

The PIPE financing was led by new investor Venrock Healthcare Capital Partners, with participation from both new and existing investors including ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, and New Enterprise Associates.

Under the subscription agreement, Korro will sell 4,501,928 common shares at $11.11 per share, and pre-funded warrants to purchase 3,148,836 shares at $11.109 per warrant. The exercise price of the pre-funded warrants is $0.001 per share. The financing is expected to close on or around Tuesday, March 10, 2026.

The Massachusetts-based biopharmaceutical company stated that net proceeds, combined with $85.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025, will extend its cash runway into the second half of 2028.

The funds will support clinical development milestones for key pipeline assets, including clinical data for KRRO-121 in urea cycle disorder patients with hyperammonemia, and the company’s GalNAc-conjugated oligonucleotide program for alpha-1 antitrypsin deficiency (subject to regulatory approval). The financing will also advance Korro’s projects targeting longevity and liver health through AMPKγ1 pathway activation.

Citigroup, Cantor, Oppenheimer & Co., and William Blair served as placement agents for the transaction. These securities were sold in a private offering and are not registered under the Securities Act of 1933.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.